Cite
Dose-tailoring of FEC adjuvant chemotherapy based on leukopenia is feasible and well tolerated. Toxicity and dose intensity in the Scandinavian Breast Group phase 3 adjuvant Trial SBG 2000-1.
MLA
Edlund, Per, et al. “Dose-Tailoring of FEC Adjuvant Chemotherapy Based on Leukopenia Is Feasible and Well Tolerated. Toxicity and Dose Intensity in the Scandinavian Breast Group Phase 3 Adjuvant Trial SBG 2000-1.” Acta Oncologica, vol. 50, no. 3, Apr. 2011, pp. 329–37. EBSCOhost, https://doi.org/10.3109/0284186X.2011.554435.
APA
Edlund, P., Ahlgren, J., Bjerre, K., Andersson, M., Bergh, J., Mouridsen, H., Holmberg, S. B., Bengtsson, N.-O., Jakobsen, E., Møøller, S., Lindman, H., & Blomqvist, C. (2011). Dose-tailoring of FEC adjuvant chemotherapy based on leukopenia is feasible and well tolerated. Toxicity and dose intensity in the Scandinavian Breast Group phase 3 adjuvant Trial SBG 2000-1. Acta Oncologica, 50(3), 329–337. https://doi.org/10.3109/0284186X.2011.554435
Chicago
Edlund, Per, Johan Ahlgren, Karsten Bjerre, Michael Andersson, Jonas Bergh, Henning Mouridsen, Stig B. Holmberg, et al. 2011. “Dose-Tailoring of FEC Adjuvant Chemotherapy Based on Leukopenia Is Feasible and Well Tolerated. Toxicity and Dose Intensity in the Scandinavian Breast Group Phase 3 Adjuvant Trial SBG 2000-1.” Acta Oncologica 50 (3): 329–37. doi:10.3109/0284186X.2011.554435.